For Whom?

Patient eligibility

While the IndiTreat® technology is suitable for multiple solid tumor types, our current portfolio focuses on stage IV (metastatic) colorectal cancer patients. We offer testing for first, third- and further-line treatments. To read more about IndiTreat® in general, please go here. For more information about solutions for specific lines of treatment, please see below.

First-line patients

Newly diagnosed patients with metastatic CRC (mCRC, synchronous metastases) or previously treated localized disease with new onset of metastases (metachronous metastases) and an indication for first-line systemic therapy are eligible for functional chemosensitivity testing using the IndiTreat® CRC Start panel.

Third-line and further-line patients

Patients with metastatic colorectal cancer (mCRC) showing tumor progression after at least two previous lines of systemic therapy are eligible for functional chemosensitivity testing using both IndiTreat® CRC Extend and IndiTreat® CRC Explore.